Literature DB >> 23765371

[Macular pathology as a cause of visual impairment?].

J Matlach1, J Nowak, J M Pérez Tejón, W Göbel.   

Abstract

This article reports a case of a pituitary adenoma as the cause of unilateral visual impairment and concomitant unilateral macular pathology. Pituitary adenomas can be classified into hormone-secreting and inactive tumors of the adenohypophysis and lead to typical symptoms in cases of hypersecretion of hormones or hypopituitarism. A pituitary adenoma classically presents with bitemporal hemianopia when compression occurs at the optic chiasm. Imaging is crucial in diagnosing pituitary adenomas. Microsurgical or endoscopic transsphenoidal surgery, hormone therapy and radiotherapy are the treatment options.

Entities:  

Mesh:

Year:  2013        PMID: 23765371     DOI: 10.1007/s00347-013-2866-2

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  6 in total

Review 1.  Treatment of pituitary tumors: surgery.

Authors:  Michael Buchfelder
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 2.  [Tumors in the region of the sella turcica].

Authors:  W Reith
Journal:  Radiologe       Date:  2009-07       Impact factor: 0.635

Review 3.  Recent advances in pituitary tumor management.

Authors:  Mark J Winder; Marc R Mayberg
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-08       Impact factor: 3.243

4.  [Initial symptoms and anamnestic time in 517 patients with pituitary adenoma].

Authors:  B Stoffel-Wagner; P Stöger; D Klingmüller
Journal:  Dtsch Med Wochenschr       Date:  1997-02-21       Impact factor: 0.628

Review 5.  Clinicopathological correlations in pituitary adenomas.

Authors:  Ozgur Mete; Sylvia L Asa
Journal:  Brain Pathol       Date:  2012-07       Impact factor: 6.508

6.  [Differential diagnosis in visual field defects of glaucoma patients].

Authors:  I Brunotte; B Haubitz; R Winter; M W Meyer
Journal:  Klin Monbl Augenheilkd       Date:  2008-02       Impact factor: 0.700

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.